A detailed history of Jpmorgan Chase & CO transactions in Exact Sciences Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 12,384,516 shares of EXAS stock, worth $512 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
12,384,516
Previous 16,690,808 25.8%
Holding current value
$512 Million
Previous $1.23 Billion 30.73%
% of portfolio
0.08%
Previous 0.13%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$56.27 - $73.77 $242 Million - $318 Million
-4,306,292 Reduced 25.8%
12,384,516 $855 Million
Q4 2023

Feb 12, 2024

SELL
$59.06 - $75.72 $94.6 Million - $121 Million
-1,601,811 Reduced 8.76%
16,690,808 $1.23 Billion
Q3 2023

Nov 14, 2023

BUY
$65.94 - $99.04 $217 Million - $326 Million
3,293,699 Added 21.96%
18,292,619 $1.25 Billion
Q2 2023

Aug 11, 2023

BUY
$62.68 - $95.05 $65.7 Million - $99.6 Million
1,048,128 Added 7.51%
14,998,920 $1.41 Billion
Q1 2023

May 18, 2023

BUY
$47.19 - $70.77 $346,280 - $519,310
7,338 Added 0.05%
13,950,792 $946 Million
Q1 2023

May 11, 2023

BUY
$47.19 - $70.77 $292 Million - $438 Million
6,193,738 Added 79.92%
13,943,454 $946 Million
Q4 2022

Feb 13, 2023

BUY
$30.35 - $53.15 $94.5 Million - $166 Million
3,115,288 Added 67.22%
7,749,716 $384 Million
Q3 2022

Nov 14, 2022

SELL
$31.97 - $49.37 $15.6 Million - $24.1 Million
-488,962 Reduced 9.54%
4,634,428 $151 Million
Q2 2022

Aug 11, 2022

SELL
$35.61 - $76.23 $4.74 Million - $10.1 Million
-133,113 Reduced 2.53%
5,123,390 $202 Million
Q1 2022

May 11, 2022

BUY
$57.56 - $82.54 $30.9 Million - $44.3 Million
537,107 Added 11.38%
5,256,503 $368 Million
Q4 2021

Feb 10, 2022

BUY
$72.5 - $100.68 $25.6 Million - $35.6 Million
353,329 Added 8.09%
4,719,396 $367 Million
Q3 2021

Nov 12, 2021

BUY
$90.24 - $124.05 $394 Million - $542 Million
4,366,067 New
4,366,067 $417 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $7.32B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.